Home > Publications Database > Sex differences in treatment effects of lecanemab and donanemab: A Bayesian reanalysis of CLARITY-AD and TRAILBLAZER-ALZ2. > print

001     281125
005     20251005002023.0
024 7 _ |a 10.1002/trc2.70155
|2 doi
024 7 _ |a pmid:40918062
|2 pmid
024 7 _ |a pmc:PMC12412750
|2 pmc
024 7 _ |a altmetric:181369906
|2 altmetric
037 _ _ |a DZNE-2025-01084
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Teipel, Stefan J
|0 P:(DE-2719)2000026
|b 0
|e First author
|u dzne
245 _ _ |a Sex differences in treatment effects of lecanemab and donanemab: A Bayesian reanalysis of CLARITY-AD and TRAILBLAZER-ALZ2.
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1759225801_23820
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a This study investigated evidence for or against a difference in treatment effect between women and men for lecanemab and donanemab.Data were derived from supplementary analyses of the regulatory studies CLARITY-AD (lecanemab) and TRAILBLAZER-ALZ2 (donanemab). Bayes factor functions were used to analyze treatment effects on Clinical Dementia Rating Sum of Boxes (CDR-SB) scores.We found moderate evidence of a lower treatment effect in women than in men for lecanemab (maximum Bayes factor = 5.97), suggesting that the presence of an effect was almost six times more likely than the absence of an effect. For donanemab, there was evidence against a treatment effect difference between women and men. There was evidence of a treatment effect difference between lecanemab and donanemab (maximum Bayes factor = 8.47) in women, but not in men.A better understanding of sex differences in treatment efficacy and their causes is urgently needed.Lecanemab was six times more likely to be ineffective than effective in women.There was no evidence of a difference between the sexes in the effect of donanemab.Lecanemab and donenamb differed in treatment efficacy in women but not in men.Future trials should include sufficient power for sex related interaction effects.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a anti‐amyloid antibodies
|2 Other
650 _ 7 |a personalized treatment
|2 Other
650 _ 7 |a prespecified secondary analysis
|2 Other
650 _ 7 |a subgroups
|2 Other
650 _ 7 |a treatment efficacy
|2 Other
700 1 _ |a Tang, Yi
|b 1
700 1 _ |a Khachaturian, Ara
|b 2
773 _ _ |a 10.1002/trc2.70155
|g Vol. 11, no. 3, p. e70155
|0 PERI:(DE-600)2832891-7
|n 3
|p e70155
|t Alzheimer's & dementia / Translational research & clinical interventions
|v 11
|y 2025
|x 2352-8737
856 4 _ |u https://pub.dzne.de/record/281125/files/DZNE-2025-01084%20SUP1.docx
856 4 _ |u https://pub.dzne.de/record/281125/files/DZNE-2025-01084%20SUP2.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281125/files/DZNE-2025-01084.pdf
856 4 _ |u https://pub.dzne.de/record/281125/files/DZNE-2025-01084%20SUP1.doc
856 4 _ |u https://pub.dzne.de/record/281125/files/DZNE-2025-01084%20SUP1.odt
856 4 _ |u https://pub.dzne.de/record/281125/files/DZNE-2025-01084%20SUP1.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/281125/files/DZNE-2025-01084%20SUP2.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281125/files/DZNE-2025-01084.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:281125
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2000026
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2025-01-07
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZH DEMENT-TRCI : 2022
|d 2025-01-07
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-08-08T17:09:24Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-08-08T17:09:24Z
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-07
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-08-08T17:09:24Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1510100
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21